Ambry Genetics, a wholly owned subsidiary of Tempus AI Inc. $(TEM)$, has announced enhancements to its Ambry CARE Program®, a digital platform that streamlines cancer risk assessment and genetic testing workflows. The update now integrates breast density into the Tyrer-Cuzick breast cancer risk score within the electronic health record, providing clinicians with more precise and personalized risk estimates to guide breast cancer screening and prevention decisions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251001225867) on October 01, 2025, and is solely responsible for the information contained therein.